Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3109 participants
OBSERVATIONAL
2012-05-31
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Blood Cell RNA-Based Cancer Detection
NCT05839834
Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study
NCT06917560
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
NCT05812027
Urine Proteome of Surgical Patients and Healthy Volunteers
NCT01538823
(COVID-19) Longitudinal Neutralizing Antibody Titers in Cancer Patients Receiving Different Anti-caner Therapies
NCT05384509
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Blood sample of the same day, or blood samples stored at 2-8°C for 3 days after collection, or serum or plasma samples stored at -20°C for those separated 3 days after collection.
Exclusion Criteria
* Small sample size insufficient for completing the testing;
* Samples not collected and processed upon the requirements of the instructions.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johnson & Johnson Medical, China
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Institute & Hospital, Chinese Academy of Medical Science
Beijing, Beijing Municipality, China
Peking University First Hospital
Beijing, Beijing Municipality, China
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China
Shanghai Blood Center
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OCD-201108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.